Cirrhosis future or investigational therapies

Revision as of 13:42, 7 September 2012 by WikiBot (talk | contribs)
Jump to navigation Jump to search

Cirrhosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cirrhosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Cirrhosis future or investigational therapies On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cirrhosis future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cirrhosis future or investigational therapies

CDC on Cirrhosis future or investigational therapies

Cirrhosis future or investigational therapies in the news

Blogs on Cirrhosis future or investigational therapies

Directions to Hospitals Treating Cirrhosis

Risk calculators and risk factors for Cirrhosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-In-Chief: Ujjwal Rastogi, M.B.B.S. [2]

Overview

Cirrhosis is a complication of Liver disease which result in irreversible [scar|scarring]] and loss of hepatocytes. Although there are many causes but Alcohol and Viral Hepatitis B and C are the main causes of cirrhosis.

Research is going on to determine the mechanism of scar formation and how to interrupt or reverse this process.

Future or Investigational Therapies

The following therapies are under trial:

Reference

  1. Lindor KD (2011). "Farnesoid X receptor agonists for primary biliary cirrhosis". Curr Opin Gastroenterol. 27 (3): 285–8. doi:10.1097/MOG.0b013e32834452c8. PMID 21297469.
  2. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B; et al. (2011). "Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection". Gastroenterology. 141 (6): 2047–55, quiz e14. doi:10.1053/j.gastro.2011.08.051. PMID 21925126.